VANCOUVER, British Columbia — November 25, 2025 — Leads & Copy — BetterLife Pharma Inc. has appointed Daniel Carcillo as a corporate advisor. Carcillo will assist the company with advancing the development of its BETR-001 drug, with a focus on treating traumatic brain injury (TBI), cluster headaches, and migraines.
Carcillo, a former professional hockey player, won two Stanley Cups with the Chicago Blackhawks. He retired at age 30 due to post-concussion syndrome after sustaining seven concussions.
After retiring from the National Hockey League (NHL) in 2015, Carcillo founded a non-profit organization to support former NHL players struggling with post-concussion syndrome and mental health issues. He also founded Wesana Health, a life sciences company that uses psilocybin-based medicine to treat traumatic brain injuries.
Carcillo said that joining BetterLife felt like the natural next step in his mission to help concussion survivors, because the company is advancing a medicine that carries the promise of psychedelic healing without the regulatory barriers, and with all the serotonergic benefits people desperately need. He added that he has lived the impact of brain trauma and knows how powerful these breakthroughs can be, and this is about giving athletes, veterans and anyone living with the invisible weight of concussion a real chance to heal and get their life back.
Dr. Ahmad Doroudian, CEO of BetterLife, said the company is excited to have Carcillo join their advisory group. He noted that Carcillo’s firsthand experience with TBI and his passion to advance the development of medicines and treatments for those injuries will provide invaluable guidance. Doroudian added that they look forward to working with Carcillo to advance the development BETR-001.
BetterLife Pharma Inc. is a biotechnology company focused on developing and commercializing BETR-001 for various neurological disorders. The drug is currently in preclinical and IND-enabling studies. It is a non-hallucinogenic and non-controlled LSD derivative that is unregulated and can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles, and its pending patent for composition and method of use covers the treatment of various neurological disorders until around 2042. BetterLife also owns a drug candidate for treating viral infections and is seeking strategic alternatives for further development.
Ahmad Doroudian, Chief Executive Officer
Email: Ahmad.Doroudian@blifepharma.com
Phone: 1-604-221-0595
Source: BetterLife Pharma
